Emyria announces interim clinical trial results for PTSD program - Biotech Dispatch

Emyria reports interim clinical results from its MDMA-assisted therapy for PTSD, showing improved outcomes for eight patients with moderate to severe PTSD. The program aims to recruit 70 patients.